Mohamed W Attwa1,2, Adnan A Kadi1, Ali S Abdelhameed1, Hassan A Alhazmi3,4. 1. Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia. 2. Students' University Hospital, Mansoura University, Mansoura 35516, Egypt. 3. Department of Pharmaceutical Chemistry, College of Pharmacy, Jazan University, Jazan, Saudi Arabia. 4. Substance Abuse and Toxicology Research Centre, Jazan University, Jazan, Saudi Arabia.
Abstract
BACKGROUND: Talazoparib (BMN673) is a new poly(ADP-ribose) polymerase inhibitor that has been FDA approved for patients suffering from metastatic breast cancer with germline BRCA mutations. METHOD AND RESULTS: In the current study, an accurate and efficient liquid chromatography-tandem mass spectrometry (LC-MS/MS) analytical methodology was developed for TZB estimation in addition to its metabolic stability assessment. TZB and lapatinib (LAP) (which is chosen as an internal standard; IS) were separated using reversed phase elution system (Hypersil C18 column) with an isocratic mobile phase. The linearity range of the established method was 5-500 ng/mL (r2 ≥ 0.999) in the human liver microsomes (HLMs) matrix. Different parameters were calculated to confirm the method sensitivity (limit of quantification was 2.0 ng/mL), and reproducibility (intra- and inter-day precision and accuracy were below 3.1%) of our methodology. For evaluation of TZB metabolic stability in HLM matrix, intrinsic clearance (9.59 µL/min/mg) and in vitro half-life (72.7 mins) were calculated. TZB treatment discontinuations were reported due to adverse events and dose accumulation, so in silico metabolic vulnerability (experimental and in silico) and toxicity assessment (in silico) of TZB were performed utilizing P450 Metabolism and DEREK modules of StarDrop software. CONCLUSION: TZB is slowly metabolized by the liver. TZB was reported to be minimally metabolized by the liver that approved our outcomes. We do recommend that plasma levels be monitored in cases when talazoparib is used for a long period of time, since it is possible for TZB to bioaccumulate after multiple doses to toxic levels. According to our knowledge, the current method is considered the first LC-MS/MS methodology for evaluating TZB metabolic stability. Further drug discovery studies can be done depending on this concept allowing the designing of new series of compounds with more safety profile through reducing side effects and improving metabolic behavior.
BACKGROUND: Talazoparib (BMN673) is a new poly(ADP-ribose) polymerase inhibitor that has been FDA approved for patients suffering from metastatic breast cancer with germline BRCA mutations. METHOD AND RESULTS: In the current study, an accurate and efficient liquid chromatography-tandem mass spectrometry (LC-MS/MS) analytical methodology was developed for TZB estimation in addition to its metabolic stability assessment. TZB and lapatinib (LAP) (which is chosen as an internal standard; IS) were separated using reversed phase elution system (Hypersil C18 column) with an isocratic mobile phase. The linearity range of the established method was 5-500 ng/mL (r2 ≥ 0.999) in the human liver microsomes (HLMs) matrix. Different parameters were calculated to confirm the method sensitivity (limit of quantification was 2.0 ng/mL), and reproducibility (intra- and inter-day precision and accuracy were below 3.1%) of our methodology. For evaluation of TZB metabolic stability in HLM matrix, intrinsic clearance (9.59 µL/min/mg) and in vitro half-life (72.7 mins) were calculated. TZB treatment discontinuations were reported due to adverse events and dose accumulation, so in silico metabolic vulnerability (experimental and in silico) and toxicity assessment (in silico) of TZB were performed utilizing P450 Metabolism and DEREK modules of StarDrop software. CONCLUSION: TZB is slowly metabolized by the liver. TZB was reported to be minimally metabolized by the liver that approved our outcomes. We do recommend that plasma levels be monitored in cases when talazoparib is used for a long period of time, since it is possible for TZB to bioaccumulate after multiple doses to toxic levels. According to our knowledge, the current method is considered the first LC-MS/MS methodology for evaluating TZB metabolic stability. Further drug discovery studies can be done depending on this concept allowing the designing of new series of compounds with more safety profile through reducing side effects and improving metabolic behavior.
Authors: Mohamed W Attwa; Adnan A Kadi; Hany W Darwish; Sawsan M Amer; Haitham Alrabiah Journal: Eur J Mass Spectrom (Chichester) Date: 2018-04-08 Impact factor: 1.067
Authors: Mohammad H Forouzanfar; Kyle J Foreman; Allyne M Delossantos; Rafael Lozano; Alan D Lopez; Christopher J L Murray; Mohsen Naghavi Journal: Lancet Date: 2011-09-14 Impact factor: 79.321
Authors: R S Obach; J G Baxter; T E Liston; B M Silber; B C Jones; F MacIntyre; D J Rance; P Wastall Journal: J Pharmacol Exp Ther Date: 1997-10 Impact factor: 4.030
Authors: Yuqiao Shen; Farah L Rehman; Ying Feng; Julia Boshuizen; Ilirjana Bajrami; Richard Elliott; Bing Wang; Christopher J Lord; Leonard E Post; Alan Ashworth Journal: Clin Cancer Res Date: 2013-07-23 Impact factor: 12.531
Authors: William J Scott; Martin F Hentemann; R Bruce Rowley; Cathy O Bull; Susan Jenkins; Ann M Bullion; Jeffrey Johnson; Anikó Redman; Arthur H Robbins; William Esler; R Paul Fracasso; Timothy Garrison; Mark Hamilton; Martin Michels; Jill E Wood; Dean P Wilkie; Hong Xiao; Joan Levy; Enrico Stasik; Ningshu Liu; Martina Schaefer; Michael Brands; Julien Lefranc Journal: ChemMedChem Date: 2016-06-16 Impact factor: 3.466
Authors: Cassandra L R van Doorn; Sanne A M Steenbergen; Kimberley V Walburg; Tom H M Ottenhoff Journal: Front Immunol Date: 2021-11-26 Impact factor: 7.561